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Introduction
Tumour initiation and progression are not simple cell-autonomous 
events limited to malignant cells, but rather complex conditions involv-
ing reciprocal and dynamic heterotypic interactions between cancer cells 
and normal cells present in their immediate vicinity. Hence, the concepts 
of tumour microenvironment and tumour–host interactions were intro-
duced to denote this complexity. The tumour microenvironment contains 
many different cell types, including endothelial cells, carcinoma-asso-
ciated fibroblasts, and immune/inflammatory cells, either derived from 
pre-existing resident cells or recruited from the bone marrow. Changes 
in the tumour microenvironment are largely orchestrated by the cancer 
cells themselves. In some circumstances, however, they can be initi-
ated and maintained by the microenvironment directly, for example as 
part of chronic inflammatory or tissue remodelling processes induced 
by infections, chemical or physical damage preceding or accompany-
ing tumourigenesis. Collectively, reciprocal heterotypic interactions in 
the tumour microenvironment dynamically contribute to promote cancer 
cell survival, proliferation, motility, invasion, and metastasis. Thereby, 
they determine local tumour progression, distant metastasis formation, 
and response (or resistance) to therapy and eventually disease outcome. 
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Tumour angiogenesis, invasion, and metastasis involve profound and 
complex tumour–host interactions. While tumour angiogenesis has been 
therapeutically targeted to provide some survival benefits, tumour inva-
sion and metastasis are conditions still lacking valid treatments. Recent 
advances in metastasis research, however, have shed new light on mech-
anisms that may open unprecedented opportunities for clinical therapies. 
In this chapter we will summarise the essentials of tumour angiogenesis 
and metastasis and highlight open questions and new opportunities for 
future therapies. 
Physiological and Pathological Angiogenesis (Figure 1)
Angiogenesis is the process of new blood vessel formation from pre- 
existing vessels. It is broadly involved in tissue and organ generation during 
development, while in the adult it is limited to a few physiological events 
such as wound healing, skeletal morphogenesis, reproductive cycle, and 
pregnancy. Angiogenesis, however, occurs in several pathological condi-
tions including chronic inflammation and cancer. The development of 
new vascular structures is crucial to support growing tissues or tumours 
with oxygen and nutrients and to allow for recirculation of immune 
surveillance cells. Angiogenesis occurs mostly by sprouting, migration, 
and proliferation of endothelial cells from pre-existing blood vessels 
(Figure 1). Several crucial pro-angiogenic factors have been iden-
tified such as vascular endothelial growth factor A (VEGF-A), 
placental growth factor (PlGF), hepatocyte growth factor (HGF), 
fibroblast growth factors (FGFs), angiopoietins, ephrins, semaphorins, 
cytokines (interleukin [IL] 6), and chemokines (e.g. IL-8, stromal 
cell-derived factor 1 [SDF-1]) (Table 1). Endogenous inhibitors of 
angiogenesis have also been reported, including thrombospondin, 
tissue inhibitors of metalloproteinases, angiostatin, or endostatin 
(Table 1). The switch to the angiogenic phenotype in specific physiologi-
cal and pathological conditions is determined by the balance between 
pro- and anti-angiogenic factors. The angiogenic switch is a hallmark of 
malignant tumour progression.
Wyss et al.
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Figure 1  Mechanisms of vascularisation. Several mechanisms of vessel formation 
in normal tissues and tumours have been described. Angiogenesis, the sprouting of 
endothelial cells from pre-existing vessels. Vasculogenesis, driven by EPCs mobilised from 
the bone marrow in response to tumour-derived chemoattractants and differentiating 
into endothelial cells. Intussusception, the splitting of a preformed vessel into two daughter 
vessels. Vessel co-option, the appropriation of a pre-existing blood vessel, especially at the 
invading front. Vascular mimicry, the replacement of the vascular endothelial cell lining by 
tumour cells. Endothelial cell differentiation from putative cancer stem cells. The first three 
modes of vascularisation occur in both physiological and pathological conditions, whereas 
the other three are only observed in tumours.
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Tumour-associated Vasculature
Tumour angiogenesis is key for tumour growth, invasion, and metastasis. 
In contrast to physiological angiogenesis, angiogenic tumour vessels are 
structurally and functionally abnormal and do not evolve to form fully 
mature vessels. Tumour vessels are very heterogeneous and chaotic with 
great variation in lumen size, excessive branching, and tortuous patterns. 
Tumour endothelial cells are poorly interconnected, leaky, and occa-
sionally multilayered. Pericyte coverage and the basement membrane 
are also abnormal. As a consequence of these structural abnormalities, 
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tumour vessel function is severely compromised. Irregular perfusion and 
leakiness are two main functional consequences, resulting in heteroge-
neous and insufficient delivery of oxygen and nutrients, increased inter-
stitial pressure, facilitated intravasation, and the escape of tumour cells. 
The deficient and abnormal functionality of the tumour vasculature has 
three important consequences. Firstly, it induces a vicious cycle of angio- 
genesis, whereby starved tumour regions further promote angiogenesis 
to attract oxygen and nutrients in a compensatory self-sustaining man-
ner. Secondly, hypoxic regions of the tumour microenvironment select 
hypoxia-resistant tumour cells that are also more aggressive and resistant 
to therapy. Thirdly, high interstitial pressure severely limits the delivery 
and diffusion of drugs, including chemotherapy, into the tumour, thus 
facilitating the selection of therapy-resistant cancer cells.
Tumours can also exploit pre-existing, normal blood vessels, particularly at 
the tumour periphery, in a process referred to as vascular co-option. Besides 
endothelial cell sprouting, additional modes of tumour vascularisation have 
been described. They include vascular mimicry, replacing the endothe-
lial cells in the vessel wall with tumour cells, differentiation of tumour 
stem cells into endothelial cells, vasculogenesis, the de-novo formation 
of endothelial cells from recruited bone marrow-derived cells (BMDCs), 
endothelial progenitor cells (EPCs), and intussusception, the splitting of 
preformed vessels into two daughter vessels (Figure 1). Additional angio- 
genic signals originating from cells of the tumour microenvironment, 
Wyss et al.
Table 1  Principal Pro- and Anti-angiogenesis Factors.
Pro-angiogenic factors Anti-angiogenic factors
Angiopoietin-1 Angiotensin 
Epidermal growth factor Endostatin
Fibroblast growth factor Thrombospondin
Hepatocyte growth factor Tissue inhibitors of metalloproteinases
Insulin-like growth factor Vasostatin 
Placental growth factor
Platelet-derived growth factor
Pleitropin
Transforming growth factors (α and β)
Vascular endothelial growth factor 
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mainly from cancer-associated fibroblasts (CAFs) producing SDF-1/
CXCL12 and infiltrating inflammatory cells secreting a variety of fac-
tors, further contribute to angiogenesis. Angiogenic inflammatory cells 
comprise a wide variety of BMDCs, including Tie2-expressing mono-
cytes (TEMs), M2-polarised tumour-associated macrophages (TAMs), or 
CD11b+ Gr1+ myeloid-derived suppressor cells which release soluble fac-
tors such as PlGF, Bv8, granulocyte-colony stimulating factor (G-CSF), 
and S100A8/9.
While physiological angiogenesis largely depends on VEGF, tumour 
angiogenesis can be induced by other factors such as FGFs, HGF, and 
SDF1. This explains, at least in part, the intrinsic or acquired resistance 
to VEGF-blockade therapy.
Anti-angiogenic Therapy in Cancer
Angiogenesis has been long considered an attractive therapeutic target 
in anti-cancer therapy. Traditionally, anti-angiogenic therapy has been 
designed to inhibit the formation of new blood vessels and to destroy 
existing ones with the purpose to starve the tumour. More recently, the 
notion of vascular normalisation, i.e. the reversal of the abnormal struc-
tural and functional features described above, has been introduced with 
the aim to improve delivery of chemotherapy. 
The prominent role of VEGF in promoting tumour angiogenesis made 
it an appealing target for therapeutic interventions. The anti-VEGF 
antibody bevacizumab has been the first United States Food and Drug 
Administration-approved anti-angiogenic drug for clinical use to treat 
several advanced, metastatic cancers (e.g. colorectal, breast, ovary, non-
small cell lung [NSCLC], kidney). Anti-VEGF therapy prolongs pro-
gression-free survival (PFS) and (only minimally) overall survival (OS). 
However, these benefits are rather limited (months). Multi-targeted pan-
VEGF receptor tyrosine kinase inhibitors such as sunitinib, pazopanib, 
sorafenib, or vandetanib have been subsequently approved for various 
metastatic cancers (Table 2). VEGF blockade decreases vascular branch-
ing, reduces homing of BMDCs, enhances endothelial cell sensitivity to 
chemotherapeutic drugs, and reduces leakiness and interstitial pressure. 
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Except for a few cancers, most notably liver cancer, kidney cancer, and 
glioblastoma, anti-angiogenic therapy provides benefit only in combi-
nation with chemotherapy. It has been proposed that anti-angiogenic 
therapy may act by facilitating the activity of chemotherapy rather than 
having anti-tumour effects itself. The mechanism for this co-operation 
between anti-angiogenic and chemotherapy drugs is not fully elucidated 
and may include increased drug delivery, sensitisation of cancer cells to 
genotoxic drugs, or elimination of cancer stem cells. As some tumour 
cells express VEGF receptors (VEGFR) and use VEGF as a survival fac-
tor, anti-VEGF therapy may also directly affect tumour cells. 
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Table 2  Therapeutic Indications for Angiogenesis Inhibitors Currently Used in the Clinic.
Drug Target Type of inhibitor Therapeutic indications 
Bevacizumab VEGFA Monoclonal antibody Colorectal cancer  
Non-small cell lung cancer  
Renal cell cancer  
Ovarian cancer
Aflibercept VEGFA/VEGFB, 
PIGF
Chimeric VEGF/PIGF
neutralising receptor
Colorectal cancer
Sorafenib VEGFR TKI Renal cell cancer  
Hepatocellular carcinoma
Sunitinib VEGFR TKI Renal cell cancer  
Gastrointestinal stromal tumour  
Pancreatic cancer (neuroendocrine 
tumour)
Pazopanib VEGFR, PDGFR, KIT TKI Renal cell cancer
Axitinib VEGFR TKI Renal cell cancer
Vandetanib VEGFR, EGFR, RET TKI Medullary thyroid cancer
Everolimus mTOR mTORC1 inhibitor Renal cell cancer  
Pancreatic cancer (neuroendocrine 
tumour)  
Breast cancer (ER+, HER2 neg)
EGFR, Epidermal growth factor receptor; ER, oestrogen receptor; HER2, human epidermal growth factor 2 receptor; mTOR, 
mammalian target of rapamycin; PDGFR, platelet-derived growth factor receptor; PlGF, placental growth factor; TKI, tyrosine kinase 
inhibitor; VEGF, vascular endothelial growth factor.
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Resistance to Anti-angiogenic Therapy
Despite the initial breakthrough of inhibiting VEGF/VEGFR in con-
trolling tumour progression, with time it has become evident that not 
all patients respond to this therapy. Tumours can be either resistant to 
anti-angiogenics at start (intrinsic resistance) or become resistant during 
treatment (acquired resistance). Recent clinical trials with anti-angio-
genic drugs in adjuvant settings showed that the initial benefit in PFS did 
not correlate with improved OS of patients, consistent with the patients’ 
development of acquired resistance to these drugs.
The mechanisms of resistance to anti-VEGF/VEGFR therapy are likely 
to be multiple and complex. One proposed mechanism is that tumours, 
besides VEGF, produce additional pro-angiogenic molecules such as 
PlGF, FGFs, or IL-8, thereby escaping VEGF/VEGFR blockade. Fur-
thermore, tumours can use modes of vascularisation other than sprouting, 
such as co-option or intussusception, which are not necessarily depend-
ent on VEGF. Further, anti-VEGF therapy can increase tumour hypoxia, 
thereby selecting hypoxia-resistant, aggressive cancer cell clones. Alter-
natively, tumours can adapt to metabolic starvation by rearranging their 
energy metabolism, for example by switching to anaerobic metabolism in 
hypoxic areas, or by importing intermediate metabolites such as pyruvate 
or lactate produced in hypoxic regions to generate high amounts of aden-
osine triphosphate (ATP) in oxygenated regions (metabolic symbiosis). 
Many strategies to overcome resistance to anti-angiogenic therapy have 
been proposed. In a recent preclinical model named “vascular promo-
tion therapy”, the chemotherapeutic agent gemcitabine was used in 
combination with the anti-angiogenic drug cilengitide and the calcium 
channel blocker verapamil to increase vessel dilatation and blood flow. 
This resulted in improved chemotherapy delivery and activity-inhibiting 
tumour growth and distant metastasis formation, which was more effec-
tive compared to gemcitabine treatment alone. This study raises the ques-
tion of whether promoting rather than inhibiting tumour perfusion may 
have better therapeutic effects. Similarly, researchers have shown that 
increased vascular permeability induced by cilengitide, tumour necrosis 
factor-alpha (TNF-α), or histamine enhances chemotherapy delivery to 
the tumour, resulting in increased therapeutic efficacy. 
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Biomarkers of Tumour Angiogenesis
No validated biomarkers to monitor tumour angiogenesis, to prospectively 
identify responding patients, and to monitor the efficacy of anti-angiogenic 
drugs exist for clinical use. Availability of such a biomarker would allow 
the stratification of cancer patients into responders and non-responders and 
to possibly predict the development of drug resistance. Many molecules, 
in particular angiogenic factors including VEGF, have been investigated, 
but none has turned out to be clinically useful. In alternative to circulat-
ing molecules, mobilised CD45--circulating EPCs have been considered as 
potential biomarkers, but with no better success. Other BMDCs, however, 
should be further explored. Recently, it has been reported that a bone mar-
row-derived immature B-cell population, CD45dim, CD31low, IgM+, IgD-, 
acts as a surrogate marker for response to multiple anti-angiogenic drugs 
in preclinical cancer models. We have shown that circulating CD11b+ cells 
in breast cancer patients, but not in healthy donors, are pro-angiogenic. 
Circulating monocytes should be further considered as potential candidate 
biomarkers or a source of biomarkers.
Invasion and Metastasis
The main cause of death among cancer patients is metastatic colonisa-
tion of distant sites leading to organ dysfunction and failure. The lack 
of effective therapies against metastatic disease represents the greatest 
challenge to efficiently treat patients with advanced cancers. Therefore, 
in order to improve a cancer patient’s survival, innovative and effective 
strategies are needed to prevent and treat the disseminated disease.
Recent advances in translational cancer research have greatly contributed 
to the understanding of the molecular and cellular mechanisms occurring 
in the tumour and in its microenvironment that promote metastasis. Deeper 
insights into these processes and translation to the clinic may raise unprec-
edented opportunities in the management of metastatic disease. 
The Metastatic Cascade
From a biologist’s point of view, metastases are the end product of an 
evolutionary process involving a sequence of discrete steps overcoming 
Wyss et al.
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the physical boundaries of the primary tumour and allowing formation 
of colonies at distant organ sites. This process is extremely inefficient 
(<0.01%). It is driven by a multitude of genetic and epigenetic altera-
tions within the cancer cell, followed by selection steps in line with the 
concept of Darwinian evolution. Genomic instability, as promoted by 
the inactivation of DNA repair mechanisms, is key to the acquisition of 
alterations necessary to gain metastatic capacity. The tumour-suppressor 
protein p53, which normally acts as a gatekeeper of genomic integrity 
by inducing cell cycle arrest or apoptosis in response to DNA damage, 
is lost in about 50% of all cancers. Inactivation of this oncosuppressor 
increases the risk of acquiring metastatic capacity. In addition, loss of 
p53 promotes the angiogenic switch and favours cancer cell resistance to 
genotoxic drugs. The tumour microenvironment, in particular inflamma-
tory cells, plays multiple critical roles in promoting metastasis.
The main events of the metastatic cascade are described below (Figure 2).
1. Local tissue invasion
The first step of the metastatic cascade is local invasion. Inflammatory 
cells and activated stromal fibroblasts produce matrix metalloproteinases, 
chemokines, and growth factors that activate migratory programmes in 
subsets of cancer cells. Those cells undergo drastic epigenetic repro-
gramming by switching from a static epithelial phenotype to a highly 
motile mesenchymal phenotype through a programme known as epithe-
lial–mesenchymal transition (EMT). EMT can be induced by several 
factors (e.g. transforming growth factor-beta [TGF-β], epidermal growth 
factor [EGF], and FGFs), pathways (e.g. Wnt/β-catenin, Notch, HIF-1α, 
and Ras), and activating transcription factors such as Slug, Snail, Twist, 
and Zeb.
2. Intravasation and circulation
After breaching the basement membrane, tumour cells penetrate hae-
matic or lymphatic vessels. Once in the blood or lymphatic circulation, 
they rapidly redistribute to distant secondary host tissues. To withstand 
mechanical shear stress and immunological attack during the travel 
within the circulatory system, circulating tumour cells (CTCs) can circu-
late as small clusters, camouflaged by platelets sticking to their surface.
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3. Arrest at distant sites
The CTCs arrest at foreign organs through mechanical trapping in the 
capillaries due to vessel size restriction or by cell surface receptor inter-
actions with endothelial cells lining the target organ vasculature.
4. Extravasation and seeding
Upon arrival at their final destination, the tumour cells engage molecular 
mechanisms to extravasate and invade the target organ. This involves the 
secretion of matrix metalloproteinases, degradation of the basal mem-
brane and the extracellular matrix, and integrin-dependent migration. 
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Figure 2  Cellular and molecular mechanisms in metastatic cancer progression. 1. At the 
site of the primary tumour, cancer cells interact with the stroma where various cell types 
are found, including fibroblasts, lymphocytes, and myeloid cells. Heterotypic interactions 
between the tumour and the stroma induce an epithelial–mesenchymal transition (EMT), 
which promotes tumour cell invasion into the adjacent tissues. 2. Gain of motility results in 
nearby vessel invasion, intravasation, and mesenchymal tumour cell shedding into the host 
circulation. 3. Survival in the blood stream is augmented by platelets covering the surface 
of the circulating tumour cells. 4. Arrest at a distant organ site can be mediated by homing 
molecules or may occur mechanically due to vessel size restriction. 5. Extravasation 
across the endothelial layer, local tissue invasion, and subsequent adaptation to the foreign 
environment are mandatory steps to avoid cell death. Alternatively, metastasis-initiating 
cells may reside in a dormant state for extended periods of time before environmental 
factors initiate mesenchymal–epithelial transition, proliferation, and colonisation resulting 
in the formation of clinically relevant metastases.
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5. Colonisation
In order to give rise to clinically detectable metastases, additional changes 
must occur in tumour cells. The reversion of EMT in a process known as 
mesenchymal–epithelial transition is necessary in order to regain prolif-
eration after migration. The non-permissive foreign environment of the 
target organ challenges the survival of tumour cells. Local immune cells 
initiate mechanisms to eliminate invading tumour cells, which have to 
adapt to the foreign tissue by co-opting the colonised tissue stroma and 
modulating the environment to their own advantage. The suppression of 
the anti-tumour immune response, the initiation of angiogenesis, and the 
release of growth and survival factors are strategies that metastatic cells 
may adopt in order to successfully colonise the secondary organ. 
Metastatic Organotropism
The propensity of a metastatic tumour cell to colonise a certain organ is 
called “organotropism”. Breast cancers, for instance, form metastases at 
many sites including the lung, bone, and liver, whereas colon and prostate 
cancers preferentially metastasise to liver and bone, respectively. This can-
not be explained by the vascular anatomy alone. The “seed and soil hypoth-
esis” proposed by Stephen Paget hypothesised that the intrinsic ability of 
tumour cells (“seeds”) to grow in a particular permissive organ (“soil”) 
determines the pattern of tumour spread. In analogy, the nature of the seed 
and its compatibility with the soil determine the outcome of the planting. 
In recent years, gene expression profiling derived from human tumour 
samples and preclinical models of organ-specific metastasis have helped 
researchers to better understand the mechanisms of organotropism. It has 
become clear that metastatic cells are distinct from the primary tumour 
on both genetic and epigenetic levels. Genome-wide transcriptome stud-
ies have identified genes that mediate metastasis to various organs, in 
particular to the bone, the lung, and the brain. Analysis of pathways 
involved with these targets elucidated their role in metastatic progres-
sion. Research has shown that most of the genetic and epigenetic altera-
tions required for metastasis formation are acquired within the primary 
tumour; only a few subsequent modifications appear to be necessary to 
unlock optimal metastatic capacity. 
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These recent discoveries have enabled researchers to take more inno-
vative approaches to preventing metastatic colonisation or treating 
established metastases. Further translational clinical trials are needed to 
validate targets and to test drugs in cancer patients with an invasive or 
aggressive tumour or metastatic disease. 
Metastatic Dormancy
Clinical evidence shows that the timeframe in which metastases develop 
differs greatly. For example, patients with pancreatic and small cell lung 
cancers often have clinically manifest metastases at the time of diagnosis 
and may die within months. In contrast, patients with breast and prostate 
cancers and melanoma develop clinically relevant metastases years or 
even decades after resection of the primary tumour. This extended latent 
phase suggests that tumour cells undergo long periods of dormancy. 
Metastatic dormancy can be defined as the ability of individual or small 
clusters of disseminated cancer cells to remain viable over prolonged 
periods of time without evidence of productive growth. Dormant tumour 
cells represent a major problem in the management of metastatic disease, 
as they are virtually undetectable (with the exception of cancer cells 
disseminated in the bone marrow) and resistant to adjuvant chemo- 
therapies designed to target rapidly proliferating cells.
Three mechanisms of dormancy have been proposed: (i) cellular dor-
mancy, i.e. the cancer cells reside in G0 cell cycle phase and do not prolif-
erate; (ii) immunological dormancy, i.e. cancer cells are kept in check by 
the immune system; (iii) angiogenic dormancy, i.e. cancer cell prolifera-
tion is counterbalanced by cell death due to the inability to induce angio-
genesis. Lack of integrin engagement with extracellular matrix anchorage 
and subsequent lack of activation of kinases (e.g. focal adhesion kinase) 
prevents the transition from a quiescent to a proliferative state. Tumour 
cells may also be exposed to stroma-derived growth-suppressive signals. 
For instance, expression of bone morphogenetic protein antagonist by 
dormant tumour cells was shown to terminate the quiescent state and 
initiate metastatic outgrowth in the lung. 
Wyss et al.
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Concluding Remarks and Outlook
The discovery and understanding that cancer progression are not fully 
cell-autonomous events but rather depend on dynamic, reciprocal inter-
actions with the surrounding normal host cells/tissue has changed the 
way we understand cancer biology nowadays, and has created oppor-
tunities for novel diagnostic and therapeutic modalities. Anti-angiogen-
esis was the first therapeutic approach to demonstrate in patients that 
targeting microenvironmental cues can lead to clinical benefits. Lack 
of biomarkers for patients’ stratification, limited survival benefits, and 
development of resistance are the main challenges in the field of anti-
angiogenic therapy. Impinging on metabolic adaptation should be con-
sidered as a strategy to counterbalance the effects of starvation on the 
tumour cells induced by anti-angiogenic drugs. Targeting the recruitment 
of inflammatory cells into the tumour microenvironment might be envis-
aged to break the vicious circle of compensatory angiogenesis following 
therapy-induced hypoxia and necrosis. Lastly, strategies increasing ves-
sel permeability should be explored in combination with chemotherapy.
The development of effective therapies to prevent and treat metastasis is 
a top priority in experimental, translational, and clinical cancer research. 
The understanding of metastasis is progressing at an unprecedented pace. 
Mechanisms have been unravelled and many potential targets identified. 
Cancer immunotherapy is providing impressive benefits in patients with 
advanced metastatic disease. Immunomodulatory therapy may be applied 
to patients at risk for metastatic progression before overt metastases appear.
Although researchers have not yet found a cure for cancer, important 
advances in treatment strategies developed in preclinical, clinical, and 
translational research studies may hopefully continue to improve the 
overall outcome for cancer patients and cancer survivors.
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